P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH.

Autor: Saraf, S., Brown, R. C., Hagar, R. W., Idowu, M., Osunkwo, I., Kalfa, T. A., Kuypers, F. A., Geib, J., Schroeder, P., Wu, E., Kelly, P., Telen, M. J.
Zdroj: HemaSphere; 2022 Supplement 3, Vol. 6, p1377-1378, 2p
Databáze: Complementary Index
Externí odkaz: